Conavi Medical Corp

Conavi Medical Corp has a negative equity position of CAD -18.03 million and a debt-to-equity ratio of -1.1, indicating a leveraged capital structure with liabilities exceeding assets. The company’s liquidity is constrained, with a current ratio of 1.01 and negative free cash flow of CAD -19.89 million, suggesting limited ability to meet short-term obligations without external financing. Profitability metrics show a return on assets (ROA) of -1.65, reflecting significant operational losses despite a gross profit of CAD 7.63 million. The company reported a net loss of CAD 20.52 million, driven by an operating loss of CAD 19.84 million, which is inconsistent with the industry’s typical focus on high-margin medical device innovation. The company operates as a single-segment entity, with all revenue derived from its Novasight Hybrid System. Geographic exposure is not disclosed, but the company is headquartered in Canada, and its product is marketed globally for use in complex percutaneous coronary interventions (PCIs). Revenue for the latest period was CAD 9.12 million, with no segment-specific growth data provided. Analysts have assigned a mean price target of CAD 1.00, with one "buy" recommendation and no "strong buy" or "hold" ratings, indicating limited near-term optimism. The company faces medium liquidity risk due to negative net cash and a high debt load of CAD 19.91 million, with no dilution risk identified in the current period. However, the absence of positive operating cash flow and the need for continued capital raises could increase dilution pressure in the future. Recent filings and transcripts have not disclosed material events, but the company’s ongoing losses and reliance on debt financing suggest a need for strategic capital management or product commercialization acceleration to improve its financial position.